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A bdominal aortic aneurysm (AAA), a progressive aortic dilation, is a common vascular disease associated with high mortality. Aneurysm results from the culmination of a series of events that lead to disruption of structural integrity and segmental weakening of the abdominal aortic wall. An incomplete understanding of the biological mechanisms underlying the disease has limited the development of therapeutic treatment and diagnostic strategies, thus leaving surgical and endovascular procedures as the only treatment options for patients with AAA.
Histologically, aneurysmal tissues are characterized by disruption of the elastic fibers in the aortic wall and extensive transmural infiltration of macrophages and lymphocytes. [1] [2] [3] These features have been consistently duplicated in animal models of AAA. 4 The prevailing view is that inflammatory cells, mainly macrophages, are the major source of matrix-degrading enzymes, such as matrix metalloproteinases [5] [6] [7] [8] [9] and proinflammatory cytokines. [10] [11] [12] Anti-inflammatory strategies, such as those that deplete neutrophils, lymphocytes, mast cells, or proinflammatory cytokines, have been shown to prevent the upregulation of matrix metalloproteinases and attenuate aneurysm formation in mouse models of AAA. [13] [14] [15] [16] Although the depletion of vascular smooth muscle cells (SMCs) is well documented in human aneurysmal tissues, 17 potential interactions between SMCs and infiltrating inflammatory cells remain unclear. We have recently demonstrated that blocking apoptosis with a pan caspase inhibitor protected mice from angiotensin II-induced aneurysm expansion. 18 The caspase inhibitor not only prevented SMC depletion but also diminished infiltration of macrophages and lymphocytes, suggesting a potential link between the apoptotic process and inflammatory signaling in the pathogenesis of aneurysm.
Protein kinase C-δ (PKCδ), a member of the PKC family of serine and threonine kinases, is a crucial mediator of SMC apoptosis. [19] [20] [21] Studies of PKCδ knockout (KO) mice reveal that mice lacking PKCδ develop normally but exhibit an apoptosis-resistant phenotype when subjected to models of vascular injury, such as vein graft or carotid artery ligation. 22, 23 Conversely, gene transfer of PKCδ via an adenoviral vector led to excessive apoptosis of vascular SMCs in a rat carotid balloon injury model. 23 More recently, we showed that PKCδ may October 2012 also be involved in the regulation of chemokine expression. Inhibition of PKCδ with rottlerin profoundly decreases the production of monocyte chemoattractant protein-1 (MCP-1) by aortic vascular SMCs and, subsequently, inhibits chemotaxis of inflammatory cells toward SMC-conditioned media. 21 We have previously shown that the expression of PKCδ is significantly higher in human aneurysmal aortic tissues as compared with normal arteries. 21 The collection of these tissues at the time of surgical repair precluded analysis of a potential causal relationship between PKCδ and aneurysm, specifically, whether PKCδ upregulation contributes to the pathophysiology of aneurysm or is merely a resultant phenomenon. To determine whether PKCδ is an integral mediator of SMC apoptosis and vascular inflammation during aneurysm pathogenesis, the current study tests the effects of PKCδ gene deficiency on aneurysm formation using the CaCl 2 mouse model. In addition, we explored the potential molecular mechanisms by which PKCδ regulates the proinflammatory signals produced by apoptotic SMCs.
Materials and Methods
A detailed description of the Materials and Methods are shown in online-only Data Supplement.
Mouse Models of AAA
The generation of PKCδ target deletion in mice was described elsewhere. 24 PKCδ KO mice and their wild-type (WT) littermates were generated by mating heterozygous pairs. C57BL/6 mice and apolipoprotein E-deficient mice were purchased from Harlan Laboratories (Madison, WI) and Jackson Laboratory (Bar Harbor, ME), respectively. Green fluorescent protein transgenic mice were gifted by Dr William Burlingham of the University of Wisconsin-Madison.
Male mice, aged 12 weeks, underwent a CaCl 2 -induced AAA model as described previously. [25] [26] [27] [28] Briefly, the infrarenal region of the aorta was isolated and treated with 0.5 mol/L CaCl 2 perivascularly via gauze for 20 minutes. Control mice were similarly treated with 0.5 mol/L of NaCl. Tissues were fixed in 4% formaldehyde in PBS, embedded and cut to 6-or 8-µm sections for optimal cutting temperature and paraffin-imbedded arteries, respectively.
Immunohistochemistry
Antibodies were purchased from Abcam (Cambridge, MA; interferon-γ, interleukin [IL]-6, monocyte+macrophage antibody, myosin heavy chain, and CD45), Santa Cruz (Santa Cruz, CA; CD3, MCP-1, Mac3, PKCδ, Ly6G, and CD68), Sigma-Aldrich (smooth muscle actin), and Cell Signaling (Danvers, MA; Cleaved caspase-3). Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining kit was purchased from Roche (Madison, WI). Van Geison stains were carried out using Chromaview Van Gieson kit (Richard Allan Scientific, Kalamazoo, MI).
Cell Culture
The murine macrophage cell line RAW264.7 cells were obtained from American Type Culture Collection (ATCC, Manassas, VA). Primary mouse aortic SMCs from the aorta of both PKCδ KO and WT mice were isolated based on a protocol described by Clowes et al. 29 
Migration Assay
In vitro migration assay was carried out, as previously described. 16 Briefly, RAW264.7 macrophages, or CD11b + cells isolated from bone marrow, were placed in a 5-µm pore Transwell insert. Conditioned and treated media were used as chemoattractants. After 6 hours of incubation, inserts were removed and stained with hematolxylin to facilitate nuclei visualization. The mean value of migrated cells was counted in 8 high-power fields per membrane.
Bone Marrow Isolation and Sorting
Bone marrow was isolated from long bones, washed with PBS, and counted. Monocytes were collected from bone marrow by magnetic sorting using CD11b microbeads (Miltenyi Biotec, Boston, MA). Purity of the resulting CD11b + cells was assessed by flow cytometry using antibodies to CD3, CD11b, and CD45/B220 (Miltenyi Biotec).
Statistical Analysis
Values were expressed as mean±SE. Experiments were repeated at least 3 times unless stated otherwise. Differences between the 2 groups were analyzed by Student t test. For time course comparison, 1-way ANOVA analysis was followed by Bonferroni correction to adjust for multiple comparisons. Values of P<0.05 were considered significant.
Results

PKCδ Expression in Experimental Aneurysms
We subjected C57BL/6 male mice to perivascular treatment of 0.5 mol/L CaCl 2 (or equal concentration of NaCl) to the infrarenal region of the aorta and euthanized the animals at selected time points. Administration of CaCl 2 led to gradual aortic dilatation associated with elastin fragmentation ( Figure  I in the online-only Data Supplement). Immunohistochemical analysis showed a profound upregulation of PKCδ protein in the aortic media 3 and 7 days after the CaCl 2 treatment ( Figure  1A) , a time frame at which aortic expansion was barely visible. The temporal and spatial pattern of PKCδ expression mirrored that of the TUNEL positivity ( Figure 1B ). Confocal images confirmed the colocalization between PKCδ upregulation and apoptosis (TUNEL). Furthermore, PKCδ-positive cells were primarily SMCs, as identified by myosin heavy chain ( Figure  1C ). A similar expression pattern of PKCδ and its association with apoptosis was also observed in angiotensin II-induced aneurysm in apolipoprotein E-deficient mice. ( Figure II in the online-only Data Supplement). Western blot analysis confirmed the elevated level of PKCδ protein in CaCl 2treated aortas as compared with the NaCl-treated controls ( Figure 1D and 1E). Additionally, levels of the apoptosisassociated catalytic fragment of PKCδ became readily detectable in CaCl 2 -treated group ( Figure 1D ).
Mice Lacking PKCδ Are Resistant to AAA Induction
To prove a potential role of PKCδ in AAA formation, we subjected PKCδ KO mice and their WT littermates to aneurysm induction by CaCl 2 . Forty-two days after the CaCl 2 treatment, abdominal aorta of WT mice were visibly inflamed and dilated whereas the arteries of KO mice appeared minimally affected (Figure 2A ). The maximal external diameter of the abdominal aorta was measured immediately before the CaCl 2 application and at the time of tissue harvest. As seen in Figure 2B , the baseline aortic diameters are comparable in PKCδ WT and KO mice. Six weeks after the CaCl 2 treatment, arteries of WT mice expanded to 1.04±0.08 mm (96.6±31%), whereas arteries of KO mice expanded only to 0.74±0.06 mm (39.7±9%) ( Figure 2B ). Similarly, PKCδ was shown to play a role in the elastase perfusion model of murine AAA. Inactive elastase produced minimal dilation of the artery in both WT and KO animals (0.77±0.06 mm and 0.76±0.02 mm, respectively; n=2), whereas active elastase treatment produced a more severe dilation in WT animals (1.47±0.16 mm) compared with KO (0.97±0.29 mm) ( Figure III in the online-only Data Supplement).
Histological analysis performed at 7 days after CaCl 2 treatment revealed similar elastin degradation in KO and WT arteries ( Figure IV in the online-only Data Supplement). However, the same histological analysis 42 days after the CaCl 2 treatment showed elastin fibers in arteries harvested from KO mice appeared continuous and organized, similar to NaCl-treated controls, whereas elastin fibers in CaCl 2 -treated WT arteries appeared fragmented and disoriented ( Figure 2C and 2D). Furthermore, PKCδ KO tissue harvested at 7 days displayed significantly reduced SMC apoptosis, as evidenced by confocal staining showing colocalization of myosin heavy chain and apoptosis (TUNEL), as compared with WT samples ( Figure 2E ). Accordingly, cleaved Caspase-3 was nearly undetectable in PKCδ KO arteries, whereas it was abundant 
PKCδ Is Critical for the Inflammatory Response
Next, we analyzed macrophage infiltration, another important characteristic of aneurysm, in the aortas of both WT and KO animals. Immunohistochemical analysis revealed a profound reduction in the number of macrophages (Mac-3 + , CD68 + ) detected in the aorta of PKCδ KO mice as compared with their WT littermates ( Figure 3A and 3B). Additionally, neutrophils (Ly6G + ), leukocytes (CD45 + ), and T cells (CD3 + ) were shown to be present in the aortic samples of the PKCδ WT mice, mostly prevalent in the adventitia, and almost entirely absent in KO aortas ( Figure VI in the online-only Data Supplement). Similarly, levels of AAA-associated inflammatory cytokines IL-6 and MCP-1 were markedly decreased by PKCδ gene deficiency ( Figure 3C ). To better quantify the altered cytokine expression, we analyzed aortic tissues using real-time polymerase chain reaction analysis. As shown in Figure 3D , PKCδ gene deficiency caused a 50.7% and 48.1% reduction in mRNA levels of IL-6 and MCP-1 in tumor necrosis factor-δ-treated SMCs, respectively. Additionally, aneurysmassociated induction of IL-1δ and IFN-δ was also significantly blunted in PKCδ KO mice ( Figure VII in the online-only Data Supplement). There was also a small but statistically insignificant trend of reduction in the tumor necrosis factor-δ mRNA abundance.
PKCδ-Deficient Aortic SMCs Are Impaired in MCP-1 Expression
The diminished inflammatory infiltrate in PKCδ KO mice could be caused by a lack of PKCδ-mediated chemokine production in the aortic wall or diminished migratory property of monocytes. A complete blood count performed on WT and KO animals showed no significant difference in white blood cell or red blood cell populations between the 2 genotypes ( Table I in Together, these data suggest that neither number nor migratory capability of bone marrow monocytes are affected by PKCδ gene deficiency.
Real-time polymerase chain reaction analysis of aortic SMCs showed KO cells to have a nearly absolute impairment of MCP-1 production. Expression of interferon-γ and IL-6 also appeared to be modulated by PKCδ, albeit to a lesser degree ( Figure 4A ). The dependence of MCP-1 expression on PKCδ was further demonstrated by ELISA measurement of MCP-1 production by cultured SMCs. After treatment with tumor necrosis factor-α, WT SMCs are shown to produce significantly more MCP-1 as compared with KO SMCs ( Figure  4B ). Furthermore, overexpression of PKCδ using adenoviralmediated gene delivery (AdPKCδ) further enhanced the production of MCP-1 in WT SMCs ( Figure 4C) .
To further test the notion that PKCδ gene deficiency reduces the presence of proinflammatory aneurysm signals produced by the aortic wall, we examined the ability of aortic SMCs to attract RAW264.7 monocyte/macrophages. As shown in Figure 4D , the number of RAW264.7 cells that migrated toward media conditioned by KO SMCs was ≈50% less than that toward media conditioned by WT SMCs. Furthermore, administration of an MCP-1-neutralizing antibody completely eliminated the ability of WT SMCs to stimulate migration, suggesting MCP-1 to be a critical proinflammatory signal released by aortic SMCs (Figure 4D ).
Exogenous PKCδ Reverses the Aneurysm-Resistant Phenotype of KO Mice
Data derived from the above in vitro analyses suggest that PKCδ gene deletion attenuates aneurysm development primarily through preventing aortic SMCs from undergoing apoptosis and producing proinflammatory chemokines, specifically MCP-1. To test this hypothesis, we developed an aortic tissue-specific gene transfer method to restore PKCδ expression in the arterial wall of KO mice. As described in the Materials and Methods section, adenovirus was administered to the aortic wall immediately after the removal of CaCl 2 . This gene transfer method produced a localized transgene expression as illustrated by using an adenovirus encoding enhanced green fluorescent protein (AdGFP). While producing abundant green fluorescent protein expression in the infrarenal region of the aortic wall, aortic administration of adenovirus encoding green fluorescent protein did not produce transgene expression in circulating white blood cells ( Figure IXA and IXB in the online-only Data Supplement).
To restore PKCδ expression in the aortas of PKCδ KO mice, adenovirus expressing either PKCδ or β-galactosidase (AdPKCδ or AdLacZ, respectively) was administered to the infrarenal aorta of PKCδ KO mice. Mice were euthanized after 7 or 42 days for histological and morphological analyses, respectively. Delivery of AdPKCδ successfully induced localized aortic expression of PKCδ in KO mice, mostly in the perivascular region and to a lesser degree in the smooth muscle actin positive media ( Figure IXC and IXD in the online-only Data Supplement). Forty-two days after the CaCl 2 treatment, AdLacZ-treated PKCδ KO mice displayed minimum aortic expansion, with a final diameter measurement of 0.67±0.07 mm (29.2±15.9%), indicating that viral infection alone did not alter the aneurysm-resistant phenotype of KO mice. In comparison, delivery of AdPKCδ produced significant aortic expansion in KO mice (final diameter 1.11±0.21 mm; 114.8±28.3%), an induction comparable with that seen in WT mice ( Figure 5A and 5B) . The apparent restoration of aneurysm formation shown to accompany aortic gene transfer of PKCδ is further evidenced by fragmented elastin fibers, as well as TUNEL-positive apoptotic cells and infiltrating monocytes/macrophages, at 7 days after surgery ( Figure 5C ). 
Aortic Inhibition of PKCδ Attenuates Aneurysm Formation in C57B/6 Mice
To further demonstrate the importance of aortic PKCδ expression in aneurysm development, we tested the effect of aortic inhibition of PKCδ. After the routine CaCl 2 treatment, C57BL/6 mice were subjected to local infection with either a dominant negative PKCδ mutant adenovirus or AdLacZ as control. Mice were euthanized after 7 or 42 days for histological and morphological analyses, respectively. As shown in Figure 5D and 5E, treatment with dominant negative PKCδ mutant produced a moderate but significant attenuation in aneurysm formation in C57B/6 mice as reflected by a reduction in aortic expansion as compared with the AdLacZtreated mice (final aortic diameter measurement 0.74±0.11 mm or 54.7±28.3%, and 1.05±0.06 mm or 126.5±15.7%, respectively). Accordingly, local inhibition of PKCδ activity diminished elastin degradation, apoptotic activity, and infiltration of monocytes/macrophages in the arterial wall ( Figure 5F ).
Exogenous MCP-1 Protein Restores Aneurysm to PKCδ KO Animals
Various studies have implicated an important role for both MCP-1/C-C chemokine receptor 2 signaling in vascular diseases, including atherosclerosis and AAA. [30] [31] [32] [33] Both in vivo and in vitro analyses within the current study indicate a reduction of MCP-1 expression caused by PKCδ gene deficiency; this prompted us to test whether delivery of exogenous MCP-1 to the arterial wall of PKCδ KO mice could restore aneurysm formation. Immediately after the CaCl 2 treatment, recombinant MCP-1 protein suspended in pluronic gel was delivered to the infrarenal aortic region of KO mice. As vehicle controls, parallel groups of KO and WT mice were treated with pluronic gel + solvent. As shown in Figure 6A and 6B, solvent-treated WT aortas developed aneurysmal expansion comparable with those previously observed in these mice at 42 days after the CaCl 2 treatment (0.84±0.04 mm; 73.7±8.2%). At this same time point, pluronic gel + solvent-treated PKCδ KO aortas maintained their aneurysm-resistant phenotype despite the administration of pluronic gel, a stark contrast to the KO aortas treated with recombinant MCP-1 (aortic diameter 0.62±0.06 mm or 27.1±12.5%, and 0.91±0.04 mm or 89.6±9.4%, respectively). Administration of recombinant MCP-1 in KO aorta created elastin degradation similar to that seen in the solvent-treated WT aorta, whereas solvent-treated KO aortas remained largely unaffected. Further histological analysis of these samples revealed a marked increase of macrophage infiltration in the MCP-1-treated mice as compared with solvent-treated PKCδ KO mice. Of note, the level of aortic SMC apoptosis in PKCδ KO mice was not significantly altered by the MCP-1 administration ( Figure 6C ).
Discussion
Our data for the first time provide direct evidence that PKCδ is an integral signaling molecule in the pathogenesis of AAA. We showed that inhibition of PKCδ, either through targeted gene deletion or overexpression of a dominant negative mutant, protected mice from developing characteristic features of aneurysm, including inflammation, disruption of elastin fibers, and loss of vascular SMCs. Additionally, the aneurysm-resistant phenotype was accompanied by diminished inflammatory infiltration, cytokine production, and medial apoptosis. These results not only confirm the importance of PKCδ in the regulation of SMC apoptosis but also indicate a novel role for this kinase in the proinflammatory signaling cascade, at least in the aneurysm setting.
Although PKCδ is ubiquitously expressed in many tissues and cell types, results reported here suggest that the role of this signaling protein in aneurysm pathophysiology may be primarily localized in vascular SMCs. Furthermore, our evidence suggests PKCδ may act largely through regulating expression of proinflammatory chemokines and cytokines, notably MCP-1. This notion is supported by several in vivo and in vitro findings: (1) PKCδ gene deficiency reduced the production of MCP-1 and other cytokines by aortic SMCs, but did not significantly alter the ability of monocytes to migrate; (2) an adenovirus-mediated delivery of PKCδ locally to the arterial wall was sufficient to rescue aneurysm development in PKCδ KO mice; (3) aorta-specific inhibition of PKCδ delivered a moderate but significant level of protection in C57B/6 mice; and (4) ectopic administration of MCP-1 to the aortic wall of PKCδ KO mice sufficiently rescued aneurysm development.
It has been postulated that vascular SMCs are the soil of AAA development. 34 Being a major source of extracellular matrix proteins, SMCs would be critical in counter balancing the upregulated proteolytic activities present in aneurysmal tissue. As such, the depletion of medial SMCs eliminates a cell population capable of directing connective tissue repair and may, thus, potentiate the degradation of the arterial wall and facilitate eventual rupture. 35 This study contains data supporting the idea that the dearth of connective tissue in AAA can be reversed in the presence of healthy SMCs, thus either preventing or even reversing aneurysm growth. Specifically, we showed that the arteries of CaCl 2 -treated KO mice sustained a similar degree of initial damage to aortic elastin fibers as WT aorta but by 42 days elastin integrity is restored in KO arteries.
Results from the current study further illustrate another important function of SMCs in vascular disease, (ie, as providing proinflammatory signals). The potential link between SMC apoptosis and the production of proinflammatory chemokines has been previously indicated in atherosclerosis. Using a mouse atherosclerosis model, Clarke et al 36 convincingly demonstrated that SMC apoptosis induces MCP-1 expression, inflammatory infiltrate, and other features of plaque rupture.
Recently, our own group demonstrated that blocking apoptosis with a pan-caspase inhibitor protected mice from angiotensin II-induced vascular inflammation and aneurysm expansion. 18 These data suggest that, although apoptosis and inflammation are most commonly considered unrelated events, apoptosis in an aneurysm setting may promote the inflammatory response. Such interaction between apoptosis and inflammation has been explored in atherosclerosis. Clarke et al 30 suggest that the proinflammatory property of apoptotic SMCs may be attributed to inhibited phagocytosis generated in the hyperlipidemic environment in atherosclerotic arteries. Although AAA is commonly associated with atherosclerosis, these 2 diseases are believed to be caused by distinct pathological processes. However, deficient phagocytosis is also being investigated as an underlying pathophysiological event in other types of inflammatory disorders, including autoimmue diseases, 31 thus warranting the exploration of this process in the pathogenesis of AAA.
Another important finding described in this work is the apparent critical role of PKCδ in MCP-1 function during formation and progression of aneurysm. In vitro and in vivo evidence suggests that impaired production of MCP-1 expression by aortic SMCs was the primary mechanism underlying the aneurysm-resistant phenotype of PKCδ KO mice. Importantly, this notion is further supported by the evidence that localized aortic administration of recombinant MCP-1 to the aorta of PKCδ KO mice restored vascular inflammation, elastin degradation, and aneurysmal expansion. Although several groups have explored the role of the CCR2/MCP-1 signaling axis in the aneurysm progression, 30, [37] [38] [39] this work provides what we believe to be the first evidence suggesting MCP-1 to be a critical downstream effector of PKCδ signaling in the pathogenesis of aneurysm.
Although our study has implicated a critical role for MCP-1 in AAA, it is important to consider the large number of cytokines that likely play a role in AAA development and progression. Our real-time polymerase chain reaction analysis identified additional cytokines that may be regulated by PKCδ and require further investigation.
Interestingly, localized aortic delivery of exogenous MCP-1 failed to reverse the apoptosis-resistant phenotype of PKCδ KO mice. A similar number of TUNEL + cells were found in MCP-1 and solvent-treated PKCδ KO mice. In contrast, a similar rescue experiment delivering exogenous PKCδ to the arterial wall restored all aneurysm-related cellular events (ie, inflammation, apoptosis, and elastin degradation in CaCl 2 PKCδ KO arteries). These results not only underscore the critical role of PKCδ in the apoptotic response of SMCs but also provide support for a novel relationship between PKCδ, MCP-1, and AAA. In the absence of this master mediator, apoptosis would be inhibited even when aortic SMCs are surrounded by infiltrating inflammatory cells, their inflammatory byproducts, and degraded elastin fibers. Based on rescue experiments presented here, as well as other data from the current and earlier reports, 19, 20 we propose a model in which PKCδ-mediated MCP-1 functions as a molecular link through which apoptotic SMCs stimulate the inflammatory process. Importantly, our model suggests that SMC apoptosis may contribute to aneurysm development primarily through the induction of inflammatory cytokines. That is, in the presence of abundant proinflammatory cytokines, such as the environment created by delivery of exogenous MCP-1 protein, the inflammatory and proteolytic events can proceed in full force without the participation of apoptosis.
Using a rat carotid balloon injury model of intimal hyperplasia, our group recently showed that PKCδ mediated the expression of MCP-1, which was critical for the migration of adventitial fibroblasts to the media and neointima. 40 In the CaCl 2 -treated aorta, we noted a marked expansion of the adventitia associated with abundant infiltration of macrophages and other inflammatory cells. Although the presence of macrophages in the adventitia is a prominent feature of AAA 30, 31, 34 and the role of adventitial fibroblasts in aneurysm has been explored to some extent by several groups, [41] [42] [43] [44] the precise relationship between adventitial fibroblasts, SMCs, and inflammatory cells in the context of AAA remains a highly interesting subject for future study. Evidence presented here shows the localization of IL-6 and macrophages predominantly in the adventitia, whereas MCP-1 production and apoptosis appears to occur primarily, though not exclusively, in the medial layer. It is also important to note that PKCδ, being a ubiquitously expressed protein, is also found in the adventitia. Whether PKCδ also contributes to aneurysm pathogenesis through adventitia cells should be explored in future studies given the prominent inflammatory response in the adventitia. However, several key questions remain to be addressed in models of AAA, for example, how adventitial fibroblasts may respond to medial SMC depletion, matrix degradation, and inflammatory cell infiltration.
Being a major signaling molecule, PKCδ can be activated by multiple extracellular and intracellular signals, including growth factors, inflammatory cytokines, mechanical stimuli, and oxidative stress. Not all of these signals are able to induce apoptosis or the production of MCP-1. It remains to be determined whether the proapoptotic and proinflammatory functions of PKCδ are exerted through the same or partially overlapping pathways. We have previously shown that mitogen-activated protein (MAP) kinase pathways are affected by PKCδ gene deficiency. 20, 45 Although the involvement of MAP kinases in the regulation of MCP-1 expression has been demonstrated, 46 the precise molecular interaction between PKCδ and MAP kinases and how this interaction may influence MCP-1 expression remains to be determined. Additionally, Liu et al 47 recently demonstrated that PKCδ mediates the stability of MCP-1 mRNA in vascular SMCs using a chemical inhibitor of PKCδ. Our group previously described the role of MAP kinases in regulation of mRNA stability in vascular SMCs, leading us to speculate that PKCδ may control MCP-1 mRNA turnover through a MAP kinase-mediated mechanism. 48 Taken together, our data show that the stress response regulating apoptosis and inflammatory signaling in the arterial wall may be largely dependent upon PKCδ upregulation. Accordingly, inhibition of PKCδ attenuated vascular inflammation and preserved tissue integrity, resulting in the prevention of aneurysm development in a CaCl 2 -induced model of AAA. Further, PKCδ gene deficiency appears to protect mice from developing aneurysm in the elastse model of AAA, as shown in Figure III in the online-only Data Supplement. Unfortunately, the potential role of PKCδ in the Angiotensin II model is yet to be explored, as our attempts to breed PKCδ -/apolipoprotein E-deficient, double KO mice were unsuccessful. However, we did show that levels of PKCδ were significantly elevated in aortas of apolipoprotein E-deficient mice treated with Angiotensin II. Taken together, we believe the elevated expression of this stress gene in human aneurysmal tissues, as well as the role we have shown it to play in mouse models, suggest it to be an attractive candidate for therapeutic target(s).
